Telix Pharmaceuticals (ASX:TLX) - CEO, Dr Christian Behrenbruch
CEO, Dr Christian Behrenbruch
Source: Telix Pharmaceuticals/Twitter
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Telix Pharmaceuticals (TLX) enters a trading halt while it plans an upcoming capital raise
  • Currently, there is no information about how much the company is aiming to raise or where the funds will be spent
  • Company shares will be paused until Monday, January 24, or when further details about the raise is released to the market
  • Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic assets
  • On the market, Telix last traded at $8.09 per share

Telix Pharmaceuticals (TLX) has entered a trading halt while it plans an upcoming capital raise.

So far, there are no details about how much the company is aiming to raise or where the funds will be spent.

Under the halt, company shares will be paused until Monday, January 24, or when further details about the raise are released to the market, whichever one comes first.

Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic assets using Molecularly Targeted Radiation.

Last month, the company dosed its first patient with TLX250-CDx for non-muscle invasive bladder cancer (NMIBC).

TLX250-CDx is being developed to determine whether “indeterminate renal masses” are either clear cell renal cell cancer or not.

The aim of this study is to evaluate the safety, biodistribution and dosing properties of the drug in patients with NMIBC.

This study will recruit 6 patients over 12 months, and if successful, will move to therapeutic studies for targeted alpha therapy.

On the market, Telix last traded at $8.09 per share.

TLX by the numbers
More From The Market Herald
The Market Herald Video

" Aurora Energy Metals (ASX:1AE) defies market pressures with solid ASX debut 

Aurora Energy Metals (ASX:1AE) continues to defy market pressures on day two of trading, with shares up…
Invictus Energy (ASX:IVZ) - Non Executive Chairman, Dr Stuart Lake

" Invictus Energy (ASX:IVZ) enters trading halt for capital raise

Invictus Energy (ASX:IVZ) has placed its shares in a trading halt pending the release of a…
Australian Vanadium (ASX:AVL) - Managing Director, Vincent Algar

" Australian Vanadium (ASX:AVL) enters mid-week trading halt

Australian Vanadium (ASX:AVL) has entered a mid-week trading halt pending an upcoming capital raising.
The Market Herald Video

" Capital raising and IPO news: Orcoda (ASX:ODA) raises for vehicle buy

Logistic tech business Orcoda (ASX:ODA) raised just over $1.25 million through a placement and share purchase plan to…